Abbott Laboratories
$97.55Change from previous close: −1.30%Absolute change: −$1.28
Valuation
Data as of October 1, 2026
Valuation multiples
- Market cap
- $169.88B
- Enterprise value
- $198.78B
- P/E (trailing 12 months)
- 31.6
- Forward P/E
- 16.1
- PEG
- 1.85
- Price/book
- 3.30
- Price/sales
- 3.65
- EV/EBITDA
- 17.0
- EV/revenue
- 4.27
Profitability and growth
- Gross margin
- 56.8%
- Operating margin
- 14.7%
- Net margin
- 11.6%
- ROE
- 10.6%
- ROA
- 5.3%
- Revenue growth (year over year)
- 13.0%
- Earnings growth (year over year)
- -47.5%
Financial health
- Total cash
- $5.6B
- Total debt
- $32.72B
- Debt/equity
- 0.63
- Current ratio
- 1.38
- Quick ratio
- 0.80
Dividends
- Annual dividend per share
- $2.52
- Dividend yield
- 2.6%
- Payout ratio
- 79.0%
- Ex-dividend date
- October 15, 2026
Analysts and estimates
- Average price target
- $120.26
- Median price target
- $120.00
- High price target
- $135.00
- Low price target
- $103.00
- Number of analysts
- 25
- Consensus
- Buy
- Forward EPS
- $6.07
- EPS estimate, current year
- $5.52
Shares and trading
- Beta
- 0.59
- Average volume
- 9.66M
- Shares outstanding
- 1.74B
- Float
- 1.72B
- Institutional ownership
- 81.8%
- Insider ownership
- 0.5%
- Short interest (% of float)
- 1.3%
- Short ratio (days)
- 2.48